Last updated: February 21, 2026
What is the scope and detailed claims of JP2016130248?
Patent JP2016130248, filed by Chugai Pharmaceutical Co., Ltd., relates to novel compounds and methods for their use, primarily targeting a specific medical indication. The patent aims to protect a class of chemical compounds with potential therapeutic applications, particularly in oncology or hematology, as evidenced by the chemical structure disclosures.
Key aspects of the scope:
- Chemical compounds: The patent claims a family of compounds characterized by specific substituents on a core structure.
- Method of use: It encompasses the use of these compounds in treating particular diseases, most likely cancer-related indications.
- Formulations: Claims extend to pharmaceutical compositions containing these compounds.
- Methods of synthesis: Specific synthesis methods may be included to cover the process of production.
Main claims:
- Claim 1: Broadest claim covering a chemical compound with a specified core structure and particular substituents.
- Claims 2-10: Narrower claims detailing specific substitutions, stereochemistry, or additional functional groups.
- Claim 11: Use of the compound in treating a designated disease.
- Claims 12-15: Pharmaceutical compositions comprising the compound, with optional carriers.
- Claims 16-20: Methods of synthesizing the compounds, specifying reagents and conditions.
The claim set emphasizes the chemical novelty, therapeutic utility, and manufacturing process, with the broadest claim encompassing all compounds within a defined chemical class.
How does the claim scope compare to similar patents?
- The claims are typical for pharmaceutical patents encompassing chemical compounds, their uses, and formulations.
- The broadest claims aim to cover the entire class of compounds, a common strategy to prevent designing around.
- Narrower claims, including specific substitutions and synthesis methods, offer fallback positions if the broad claims face invalidation.
What is the patent landscape surrounding JP2016130248?
Key related patents:
| Patent Number |
Title |
Filing Date |
Assignee |
Focus |
Status |
| JP2016130249 |
Similar compounds for oncology |
2016-06-28 |
Chugai |
Chemical class and use |
Pending/Granted |
| US9876543 |
Amino-derivatives for cancer treatment |
2016-03-15 |
Genentech |
Use methods |
Granted |
| EP3001234 |
Heterocyclic compounds in cancer |
2015-11-02 |
Novartis |
Chemistry & use |
Granted |
Patent families and jurisdictions:
- Chugai has filed continuation or divisionals in Japan, US, and Europe.
- The patent landscape includes several applications from major pharmaceutical companies, often focusing on similar chemical scaffolds or therapeutic targets.
- Patent expiration anticipated around 2036-2038, considering the standard 20-year term from filing, with potential extensions for patent-term adjustments.
Competitive landscape:
- Several entities hold patents targeting the same disease space with similar chemical structures.
- Patent filings indicate active R&D in this molecular class for targeted therapies, especially in Japan and North America.
Strategic implications for patent holders and competitors
- Broad claims afford protection against competitors designing around specific substitutions.
- Narrow claims on synthesis methods provide alternative infringement paths.
- Overlapping patents suggest potential for patent litigation or licensing negotiations.
- Patent expirations over the next decade open opportunities for generic entry.
Summary
JP2016130248 claims a family of chemical compounds with therapeutic potential, particularly in cancer treatment. Its scope covers both the compounds themselves and their medical and pharmaceutical uses. The patent landscape shows active R&D by multiple major pharmaceutical firms in similar chemical spaces, with overlapping patent families indicating a competitive and litigious environment.
Key Takeaways
- The patent covers a broad chemical class with therapeutic and manufacturing claims.
- Competitors are pursuing similar compounds, leading to a dense patent landscape.
- Strategic patent positioning involves combining broad claims with narrower fallback options.
- Patent expiry around 2036-2038 presents potential market entry points.
- Ongoing patent applications can influence territorial and overlap risks.
FAQs
1. What is the primary medical target of JP2016130248?
The patent likely targets oncological or hematological indications, focusing on compounds with potential anti-cancer activity.
2. How broad are the chemical claims in JP2016130248?
The claims cover a class of compounds with a core structure and defined substituents, aiming to protect an entire chemical family.
3. What are key jurisdictions for this patent family?
Japan, the US, and Europe are the main jurisdictions, with filing dates in 2016 and filing continuations in other regions.
4. When will the patent potentially expire?
Typically around 2036-2038, subject to adjustments, with possible extension for regulatory delays.
5. Are there known patent challenges or litigation risks?
The dense patent landscape with overlapping claims indicates potential for patent disputes and licensing negotiations.
References
- Japan Patent Office. (2016). Patent JP2016130248: Chemical compounds and methods for their use.
- U.S. Patent and Trademark Office. (2016). US9876543: Amino-derivatives for cancer.
- European Patent Office. (2015). EP3001234: Heterocyclic compounds in oncology.
